GLP-1s like Ozempic and Zepbound transformed obesity and diabetes treatment. But when shortages hit, compounding pharmacies and telehealth startups filled the gap with off-brand versions—cheap, accessible, and often unregulated.Now, that workaround is over.In this episode, we examine the FDA’s sweeping May 2025 ban on compounded GLP-1 drugs. What triggered it? What are the safety risks? And why is the industry suddenly pivoting to an older, less effective drug: liraglutide?With interviews, data, and regulatory context, we break down:Why Olympia Pharmaceuticals stopped producing semaglutideWhy liraglutide is gaining traction despite its limitationsWhat the FDA has reported about dosing errors, hospitalizations, and even deathsHow insurance gaps and policy shifts continue to limit accessWhat healthcare professionals should consider when restarting patients or navigating new formulariesThis isn’t just a regulatory update—it’s a turning point in the story of obesity treatment in America.

Ver todos los episodios